FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. | 20549 |
|-------------|------|-------|
|-------------|------|-------|

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL             |           |  |  |  |  |  |  |  |  |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number:              | 3235-0287 |  |  |  |  |  |  |  |  |
| Estimated average burden |           |  |  |  |  |  |  |  |  |
| hours per response:      | 0.5       |  |  |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person*  Lydon Nicholas  (Last) (First) (Middle)  C/O BLUEPRINT MEDICINES CORPORATION  45 SIDNEY STREET |  |  |   |  |  |  | Issuer Name and Ticker or Trading Symbol     Blueprint Medicines Corp [ BPMC ]      Jate of Earliest Transaction (Month/Day/Year)     05/23/2022 |            |  |  |                  |  |   |                                       |         | k all applic<br>Directo<br>Officer<br>below)   | cable)<br>r<br>(give title  |      | 10% Ov<br>Other (s<br>below)   | vner                                  |
|--|--|--|---|--|--|--|--|------------|--|--|------------------|--|---|---------------------------------------|---------|--|---|------|--|---------------------------------------|
| (Street) CAMBR (City)  |  |  | 02139<br>(Zip)  |  | - 4.1                                  | 4. If Amendment, Date of Original Filed (Month/Day/Year) |  |            |  |  |                  |  |   | 6. Indi<br>Line)<br>X                 | Form fi | or Joint/Group Filing (Check Applicable m filed by One Reporting Person m filed by More than One Reporting son |   |      |  |                                       |
|  | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned   |  |   |  |  |  |  |            |  |  |                  |  |   |                                       |         |  |   |      |  |                                       |
| 1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)  |  |  |   |  | action                                 | ction 2A. Deemed Execution Date,                         |  | 3.<br>Trai | 3. 4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5) |  | ed (A) c         | or 5. Amou<br>4 and Securitie<br>Beneficia |   | nt of 6. Over the form (D) of (I) (Ir |         | n: Direct<br>r Indirect<br>estr. 4)  | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4)                         |      |  |                                       |
|  |  |  |   |  |  |  |  |            | Cod  | e V  | Amou             | ınt  | t (A) or Pr   |                                       | e       | Transaction(s)<br>(Instr. 3 and 4)   |   |      |  | (111511.4)                            |
| Common Stock 05/23/2   |  |  |   |  | 3/202                                  | /2022  |  | М          | $\dagger$  | 10   | 10,909 A \$      |  | \$1   | 9.53                                  | 50,584  |  |   | D    |  |                                       |
|  | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |  |   |  |  |  |  |            |  |  |                  |  |   |                                       |         |  |   |      |  |                                       |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)  | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security  | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) |  | 4.<br>Transaction<br>Code (Instr<br>8) |  |  |            | Expira   | 6. Date Exercisable a<br>Expiration Date<br>(Month/Day/Year) |                  |  | d 7. Title and Am<br>of Securities<br>Underlying<br>Derivative Secu<br>(Instr. 3 and 4) |                                       |         | . Price of<br>erivative<br>ecurity<br>nstr. 5)   | 9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4) | illy | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | Beneficial<br>Ownership<br>(Instr. 4) |
|  |  |  |   |  | Code                                   | v  | (A)  | (D)        | Date<br>Exerci   | sable  | Expirati<br>Date | on   | Title   | Amou<br>or<br>Numb<br>of<br>Share     | oer     |  |   |      |  |                                       |
| Stock<br>Option<br>(Right to<br>Buy)   | \$19.53  | 05/23/2022                                 |   |  | М                                      |  |  | 10,909     | (1   | )  | 06/23/20         | )26  | Common<br>Stock   | 10,9                                  | 09      | \$0  | 0   |      | D  |                                       |

## **Explanation of Responses:**

1. This option was granted on June 23, 2016 and is fully vested.

/s/ Ariel Hurley, Attorney-in-

05/25/2022

Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.